Aik-choon Tan - Publications

Affiliations: 
Medicine University of Colorado Anschutz Medical Campus, Denver, Aurora, CO 

77 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2018 Kessler BE, Mishall KM, Kellett MD, Clark EG, Pugazhenthi U, Pozdeyev N, Kim J, Tan AC, Schweppe RE. Resistance to Src inhibition alters the BRAF-mutant tumor secretome to promote an invasive phenotype and therapeutic escape through a FAK>p130Cas>c-Jun signaling axis. Oncogene. PMID 30531837 DOI: 10.1038/s41388-018-0617-1  0.44
2018 Suda K, Murakami I, Yu H, Kim J, Tan AC, Mizuuchi H, Rozeboom LM, Ellison K, Rivard CJ, Mitsudomi T, Hirsch FR. CD44 facilitates epithelial to mesenchymal transition phenotypic change at acquisition of resistance to EGFR kinase inhibitors in lung cancer. Molecular Cancer Therapeutics. PMID 30049789 DOI: 10.1158/1535-7163.MCT-17-1279  0.44
2018 Suda K, Kim J, Murakami I, Rozeboom L, Shimoji M, Shimizu S, Rivard CJ, Mitsudomi T, Tan AC, Hirsch FR. Innate genetic evolution of lung cancers and spatial heterogeneity: analysis of treatment naïve lesions. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 29933065 DOI: 10.1016/j.jtho.2018.05.039  0.44
2018 Kim J, Yoo M, Shin J, Kim H, Kang J, Tan AC. Systems Pharmacology-Based Approach of Connecting Disease Genes in Genome-Wide Association Studies with Traditional Chinese Medicine. International Journal of Genomics. 2018: 7697356. PMID 29765977 DOI: 10.1155/2018/7697356  0.44
2018 Hintzsche JD, Yoo M, Kim J, Amato CM, Robinson WA, Tan AC. IMPACT web portal: oncology database integrating molecular profiles with actionable therapeutics. Bmc Medical Genomics. 11: 26. PMID 29697364 DOI: 10.1186/s12920-018-0350-1  0.44
2018 Yoo M, Shin J, Kim H, Kim J, Kang J, Tan AC. Exploring the molecular mechanisms of Traditional Chinese Medicine components using gene expression signatures and connectivity map. Computer Methods and Programs in Biomedicine. PMID 29650251 DOI: 10.1016/j.cmpb.2018.04.002  0.44
2018 Keysar S, Eagles J, Miller B, Jackson BC, Chowdhury FN, Reisinger J, Chimed TS, Le PN, Morton JJ, Somerset H, Varella-Garcia M, Tan AC, Song JI, Bowles DW, Reyland ME, et al. Salivary gland cancer patient-derived xenografts enable characterization of cancer stem cells and new gene fusions associated with tumor progression. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29555661 DOI: 10.1158/1078-0432.CCR-17-3871  0.32
2018 Pilling AB, Kim J, Estrada-Bernal A, Zhou Q, Le AT, Singleton KR, Heasley LE, Tan AC, DeGregori J, Doebele RC. ALK is a critical regulator of the MYC-signaling axis in ALK positive lung cancer. Oncotarget. 9: 8823-8835. PMID 29507657 DOI: 10.18632/oncotarget.24260  0.44
2018 Klauck PJ, Bagby SM, Capasso A, Bradshaw-Pierce EL, Selby HM, Spreafico A, Tentler JJ, Tan AC, Kim J, Arcaroli JJ, Purkey A, Messersmith WA, Kuida K, Gail Eckhardt S, Pitts TM. Antitumor activity of the polo-like kinase inhibitor, TAK-960, against preclinical models of colorectal cancer. Bmc Cancer. 18: 136. PMID 29402316 DOI: 10.1186/s12885-018-4036-z  0.44
2018 Kim S, Park D, Choi Y, Lee K, Kim B, Jeon M, Kim J, Tan AC, Kang J. A Pilot Study of Biomedical Text Comprehension using an Attention-Based Deep Neural Reader: Design and Experimental Analysis. Jmir Medical Informatics. 6: e2. PMID 29305341 DOI: 10.2196/medinform.8751  0.44
2017 Ionkina AA, Tentler JJ, Kim J, Capasso A, Pitts TM, Ryall KA, Howison RR, Kabos P, Sartorius CA, Tan AC, Eckhardt SG, Diamond JR. Efficacy and Molecular Mechanisms of Differentiated Response to the Aurora and Angiogenic Kinase Inhibitor ENMD-2076 in Preclinical Models of p53-Mutated Triple-Negative Breast Cancer. Frontiers in Oncology. 7: 94. PMID 28555173 DOI: 10.3389/fonc.2017.00094  0.44
2017 Hintzsche JD, Gorden NT, Amato CM, Kim J, Wuensch KE, Robinson SE, Applegate AJ, Couts KL, Medina TM, Wells KR, Wisell JA, McCarter MD, Box NF, Shellman YG, Gonzalez RC, ... ... Tan AC, et al. Whole-exome sequencing identifies recurrent SF3B1 R625 mutation and comutation of NF1 and KIT in mucosal melanoma. Melanoma Research. PMID 28296713 DOI: 10.1097/CMR.0000000000000345  0.44
2017 Dimberg L, Towers CG, Behbakht K, Hotz T, Kim J, Fosmire SP, Porter CC, Tan AC, Thorburn A, Ford HL. A genome-wide loss-of-function screen identifies SLC26A2 as a novel mediator of TRAIL resistance. Molecular Cancer Research : McR. PMID 28108622 DOI: 10.1158/1541-7786.MCR-16-0234  0.44
2017 Keysar SB, Le PN, Miller B, Jackson BC, Eagles JR, Nieto C, Kim J, Tang B, Glogowska MJ, Morton JJ, Padilla-Just N, Gomez K, Warnock E, Reisinger J, Arcaroli JJ, ... ... Tan AC, et al. Regulation of Head and Neck Squamous Cancer Stem Cells by PI3K and SOX2. Journal of the National Cancer Institute. 109. PMID 27634934 DOI: 10.1093/jnci/djw189  0.44
2016 Zhang G, Scarborough H, Kim J, Rozhok AI, Chen YA, Zhang X, Song L, Bai Y, Fang B, Liu RZ, Koomen J, Tan AC, Degregori J, Haura EB. Coupling an EML4-ALK-centric interactome with RNA interference identifies sensitizers to ALK inhibitors. Science Signaling. 9: rs12. PMID 27811184 DOI: 10.1126/scisignal.aaf5011  0.44
2016 Gregory MA, D'Alessandro A, Alvarez-Calderon F, Kim J, Nemkov T, Adane B, Rozhok AI, Kumar A, Kumar V, Pollyea DA, Wempe MF, Jordan CT, Serkova NJ, Tan AC, Hansen KC, et al. ATM/G6PD-driven redox metabolism promotes FLT3 inhibitor resistance in acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America. 113: E6669-E6678. PMID 27791036 DOI: 10.1073/pnas.1603876113  0.44
2016 Bagby S, Messersmith WA, Pitts TM, Capasso A, Varella-Garcia M, Klauck PJ, Kim J, Tan AC, Eckhardt SG, Tentler JJ, Arcaroli J. Development and Maintenance of a Preclinical Patient Derived Tumor Xenograft Model for the Investigation of Novel Anti-Cancer Therapies. Journal of Visualized Experiments : Jove. PMID 27768028 DOI: 10.3791/54393  0.44
2016 Scarborough HA, Helfrich BA, Casas-Selves M, Schuller A, Grosskurth SE, Kim J, Tan AC, Chan DC, Zhang Z, Zaberezhnyy V, Bunn PA, DeGregori J. AZ1366: An inhibitor of tankyrase and the canonical Wnt pathway that limits the persistence of non-small cell lung cancer cells following EGFR inhibition. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 27663586 DOI: 10.1158/1078-0432.CCR-16-1179  0.44
2016 Cavalli G, Koenders M, Kalabokis V, Kim J, Tan AC, Garlanda C, Mantovani A, Dagna L, Joosten LA, Dinarello CA. Treating experimental arthritis with the innate immune inhibitor interleukin-37 reduces joint and systemic inflammation. Rheumatology (Oxford, England). PMID 27567100 DOI: 10.1093/rheumatology/kew325  0.44
2016 Helfrich BA, Kim J, Gao D, Chan DC, Zhang Z, Tan AC, Bunn PA. Barasertib,(AZD1152)a small molecule Aurora B inhibitor, inhibits the growth of SCLC cell lines in vitro and in vivo. Molecular Cancer Therapeutics. PMID 27496133 DOI: 10.1158/1535-7163.MCT-16-0298  0.44
2016 Beadnell TC, Mishall KM, Zhou Q, Riffert SM, Wuensch KE, Kessler BE, Corpuz ML, Jing X, Kim J, Wang G, Tan AC, Schweppe RE. The Mitogen Activated Protein Kinase Pathway Facilitates Resistance to the Src Inhibitor, Dasatinib, in Thyroid Cancer. Molecular Cancer Therapeutics. PMID 27222538 DOI: 10.1158/1535-7163.MCT-15-0702  0.44
2016 Lee K, Lee S, Park S, Kim S, Kim S, Choi K, Tan AC, Kang J. BRONCO: Biomedical entity Relation ONcology COrpus for extracting gene-variant-disease-drug relations. Database : the Journal of Biological Databases and Curation. 2016. PMID 27074804 DOI: 10.1093/database/baw043  0.44
2016 Hintzsche J, Kim J, Yadav V, Amato C, Robinson SE, Seelenfreund E, Shellman Y, Wisell J, Applegate A, McCarter M, Box N, Tentler J, De S, Robinson WA, Tan AC. IMPACT: a whole-exome sequencing analysis pipeline for integrating molecular profiles with actionable therapeutics in clinical samples. Journal of the American Medical Informatics Association : Jamia. PMID 27026619 DOI: 10.1093/jamia/ocw022  0.44
2016 Symonds JM, Ohm AM, Tan AC, Reyland ME. PKCδ regulates integrin αVβ3 expression and transformed growth of K-ras dependent lung cancer cells. Oncotarget. PMID 26918447 DOI: 10.18632/oncotarget.7560  0.44
2015 Bowles DW, Keysar SB, Eagles JR, Wang G, Glogowska MJ, McDermott JD, Le PN, Gao D, Ray CE, Rochon PJ, Roop DR, Tan AC, Serracino HS, Jimeno A. A pilot study of cetuximab and the hedgehog inhibitor IPI-926 in recurrent/metastatic head and neck squamous cell carcinoma. Oral Oncology. PMID 26705064 DOI: 10.1016/j.oraloncology.2015.11.014  0.32
2015 Towers CG, Guarnieri AL, Micalizzi DS, Harrell JC, Gillen AE, Kim J, Wang CA, Oliphant MU, Drasin DJ, Guney MA, Kabos P, Sartorius CA, Tan AC, Perou CM, Espinosa JM, et al. The Six1 oncoprotein downregulates p53 via concomitant regulation of RPL26 and microRNA-27a-3p. Nature Communications. 6: 10077. PMID 26687066 DOI: 10.1038/ncomms10077  0.44
2015 Ryall KA, Kim J, Klauck PJ, Shin J, Yoo M, Ionkina A, Pitts TM, Tentler JJ, Diamond JR, Eckhardt S, Heasley LE, Kang J, Tan AC. An integrated bioinformatics analysis to dissect kinase dependency in triple negative breast cancer. Bmc Genomics. 16: S2. PMID 26681397 DOI: 10.1186/1471-2164-16-S12-S2  0.44
2015 Tan AC, Ryall KA, Huang PH. Expanding the computational toolbox for interrogating cancer kinomes. Pharmacogenomics. PMID 26666839 DOI: 10.2217/pgs.15.154  0.44
2015 Henry CJ, Casás-Selves M, Kim J, Zaberezhnyy V, Aghili L, Daniel AE, Jimenez L, Azam T, McNamee EN, Clambey ET, Klawitter J, Serkova NJ, Tan AC, Dinarello CA, DeGregori J. Aging-associated inflammation promotes selection for adaptive oncogenic events in B cell progenitors. The Journal of Clinical Investigation. PMID 26551682 DOI: 10.1172/JCI83024  0.44
2015 Lieu CH, Klauck PJ, Henthorn PK, Tentler JJ, Tan AC, Spreafico A, Selby HM, Britt BC, Bagby SM, Arcaroli JJ, Messersmith WA, Pitts TM, Eckhardt SG. Antitumor activity of a potent MEK inhibitor, TAK-733, against colorectal cancer cell lines and patient derived xenografts. Oncotarget. PMID 26439693 DOI: 10.18632/oncotarget.5949  0.44
2015 Singleton KR, Hinz TK, Kleczko EK, Marek LA, Kwak J, Harp T, Kim J, Tan AC, Heasley LE. Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCC. Cancer Research. 75: 4398-406. PMID 26359452 DOI: 10.1158/0008-5472.CAN-15-0509  0.44
2015 Ryall KA, Shin J, Yoo M, Hinz TK, Kim J, Kang J, Heasley LE, Tan AC. Identifying kinase dependency in cancer cells by integrating high-throughput drug screening and kinase inhibition data. Bioinformatics (Oxford, England). PMID 26206305 DOI: 10.1093/bioinformatics/btv427  0.44
2015 Arcaroli JJ, Tai WM, McWilliams R, Bagby S, Blatchford PJ, Varella-Garcia M, Purkey A, Quackenbush KS, Song EK, Pitts TM, Gao D, Lieu C, McManus M, Tan AC, Zheng X, et al. A NOTCH1 Gene Copy Number Gain is a Prognostic Indicator of Worse Survival and a Predictive Biomarker to a Notch1 Targeting Antibody in Colorectal Cancer. International Journal of Cancer. Journal International Du Cancer. PMID 26152787 DOI: 10.1002/ijc.29676  0.44
2015 Saha A, Jeon M, Tan AC, Kang J. iCOSSY: An Online Tool for Context-Specific Subnetwork Discovery from Gene Expression Data. Plos One. 10: e0131656. PMID 26147457 DOI: 10.1371/journal.pone.0131656  0.44
2015 Davis SL, Robertson KM, Pitts TM, Tentler JJ, Bradshaw-Pierce EL, Klauck PJ, Bagby SM, Hyatt SL, Selby HM, Spreafico A, Ecsedy JA, Arcaroli JJ, Messersmith WA, Tan AC, Eckhardt SG. Combined inhibition of MEK and Aurora A kinase in KRAS/PIK3CA double-mutant colorectal cancer models. Frontiers in Pharmacology. 6: 120. PMID 26136684 DOI: 10.3389/fphar.2015.00120  0.44
2015 Davis EM, Kim J, Menasche BL, Sheppard J, Liu X, Tan AC, Shen J. Comparative Haploid Genetic Screens Reveal Divergent Pathways in the Biogenesis and Trafficking of Glycophosphatidylinositol-Anchored Proteins. Cell Reports. 11: 1727-36. PMID 26074080 DOI: 10.1016/j.celrep.2015.05.026  0.44
2015 Göke F, Franzen A, Hinz TK, Marek LA, Yoon P, Sharma R, Bode M, von Mässenhausen A, Lankat-Buttgereit B, Göke A, Golletz C, Kirsten R, Boehm D, Vogel W, Kleczko EK, ... ... Tan AC, et al. FGFR1 expression levels predict BGJ398-sensitivity of FGFR1-dependent head and neck squamous cell cancers. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 26015511 DOI: 10.1158/1078-0432.CCR-14-3357  0.44
2015 Yoo M, Shin J, Kim J, Ryall KA, Lee K, Lee S, Jeon M, Kang J, Tan AC. DSigDB: drug signatures database for gene set analysis. Bioinformatics (Oxford, England). PMID 25990557 DOI: 10.1093/bioinformatics/btv313  0.44
2015 Kleczko EK, Kim J, Keysar SB, Heasley LR, Eagles JR, Simon M, Marshall ME, Singleton KR, Jimeno A, Tan AC, Heasley LE. An Inducible TGF-β2-TGFβR Pathway Modulates the Sensitivity of HNSCC Cells to Tyrosine Kinase Inhibitors Targeting Dominant Receptor Tyrosine Kinases. Plos One. 10: e0123600. PMID 25946135 DOI: 10.1371/journal.pone.0123600  0.44
2015 Yonekawa T, Gamez G, Kim J, Tan AC, Thorburn J, Gump J, Thorburn A, Morgan MJ. RIP1 negatively regulates basal autophagic flux through TFEB to control sensitivity to apoptosis. Embo Reports. 16: 700-8. PMID 25908842 DOI: 10.15252/embr.201439496  0.44
2015 Tentler JJ, Ionkina AA, Tan AC, Newton TP, Pitts TM, Glogowska MJ, Kabos P, Sartorius CA, Sullivan KD, Espinosa JM, Eckhardt SG, Diamond JR. p53 Family Members Regulate Phenotypic Response to Aurora Kinase A Inhibition in Triple-Negative Breast Cancer. Molecular Cancer Therapeutics. 14: 1117-29. PMID 25758253 DOI: 10.1158/1535-7163.MCT-14-0538-T  0.44
2015 Ryall KA, Tan AC. Systems biology approaches for advancing the discovery of effective drug combinations. Journal of Cheminformatics. 7: 7. PMID 25741385 DOI: 10.1186/s13321-015-0055-9  0.44
2015 Drasin DJ, Guarnieri AL, Neelakantan D, Kim J, Cabrera JH, Wang CA, Zaberezhnyy V, Gasparini P, Cascione L, Huebner K, Tan AC, Ford HL. TWIST1-Induced miR-424 Reversibly Drives Mesenchymal Programming while Inhibiting Tumor Initiation. Cancer Research. 75: 1908-21. PMID 25716682 DOI: 10.1158/0008-5472.CAN-14-2394  0.44
2015 Fleenor CJ, Rozhok AI, Zaberezhnyy V, Mathew D, Kim J, Tan AC, Bernstein ID, DeGregori J. Contrasting roles for C/EBPα and Notch in irradiation-induced multipotent hematopoietic progenitor cell defects. Stem Cells (Dayton, Ohio). 33: 1345-58. PMID 25546133 DOI: 10.1002/stem.1936  0.44
2015 Micel LN, Tentler JJ, Tan AC, Selby HM, Brunkow KL, Robertson KM, Davis SL, Klauck PJ, Pitts TM, Gangolli E, Fabrey R, O'Connell SM, Vincent PW, Eckhardt SG. Antitumor activity of the MEK inhibitor TAK-733 against melanoma cell lines and patient-derived tumor explants. Molecular Cancer Therapeutics. 14: 317-25. PMID 25376610 DOI: 10.1158/1535-7163.MCT-13-1012  0.44
2015 Song EK, Tai WM, Messersmith WA, Bagby S, Purkey A, Quackenbush KS, Pitts TM, Wang G, Blatchford P, Yahn R, Kaplan J, Tan AC, Atreya CE, Eckhardt G, Kelley RK, et al. Potent antitumor activity of cabozantinib, a c-MET and VEGFR2 inhibitor, in a colorectal cancer patient-derived tumor explant model. International Journal of Cancer. Journal International Du Cancer. 136: 1967-75. PMID 25242168 DOI: 10.1002/ijc.29225  0.44
2014 Pitts TM, Newton TP, Bradshaw-Pierce EL, Addison R, Arcaroli JJ, Klauck PJ, Bagby SM, Hyatt SL, Purkey A, Tentler JJ, Tan AC, Messersmith WA, Eckhardt SG, Leong S. Dual pharmacological targeting of the MAP kinase and PI3K/mTOR pathway in preclinical models of colorectal cancer. Plos One. 9: e113037. PMID 25401499 DOI: 10.1371/journal.pone.0113037  0.44
2014 Seelenfreund E, Robinson WA, Amato CM, Tan AC, Kim J, Robinson SE. Long term storage of dry versus frozen RNA for next generation molecular studies. Plos One. 9: e111827. PMID 25380187 DOI: 10.1371/journal.pone.0111827  0.44
2014 Wang CA, Drasin D, Pham C, Jedlicka P, Zaberezhnyy V, Guney M, Li H, Nemenoff R, Costello JC, Tan AC, Ford HL. Homeoprotein Six2 promotes breast cancer metastasis via transcriptional and epigenetic control of E-cadherin expression. Cancer Research. 74: 7357-70. PMID 25348955 DOI: 10.1158/0008-5472.CAN-14-0666  0.44
2014 Kim J, Vasu VT, Mishra R, Singleton KR, Yoo M, Leach SM, Farias-Hesson E, Mason RJ, Kang J, Ramamoorthy P, Kern JA, Heasley LE, Finigan JH, Tan AC. Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics (Oxford, England). 30: 2393-8. PMID 24812339 DOI: 10.1093/bioinformatics/btu323  0.44
2014 Wynes MW, Hinz TK, Gao D, Martini M, Marek LA, Ware KE, Edwards MG, Böhm D, Perner S, Helfrich BA, Dziadziuszko R, Jassem J, Wojtylak S, Sejda A, Gozgit JM, ... ... Tan AC, et al. FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 3299-309. PMID 24771645 DOI: 10.1158/1078-0432.CCR-13-3060  0.44
2014 Morrison JA, Pike LA, Sams SB, Sharma V, Zhou Q, Severson JJ, Tan AC, Wood WM, Haugen BR. Thioredoxin interacting protein (TXNIP) is a novel tumor suppressor in thyroid cancer. Molecular Cancer. 13: 62. PMID 24645981 DOI: 10.1186/1476-4598-13-62  0.44
2014 Saha A, Tan AC, Kang J. Automatic context-specific subnetwork discovery from large interaction networks. Plos One. 9: e84227. PMID 24392115 DOI: 10.1371/journal.pone.0084227  0.44
2014 Jeon M, Lee S, Lee K, Tan AC, Kang J. BEReX: Biomedical Entity-Relationship eXplorer. Bioinformatics (Oxford, England). 30: 135-6. PMID 24149052 DOI: 10.1093/bioinformatics/btt598  0.44
2013 Davies KD, Mahale S, Astling DP, Aisner DL, Le AT, Hinz TK, Vaishnavi A, Bunn PA, Heasley LE, Tan AC, Camidge DR, Varella-Garcia M, Doebele RC. Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. Plos One. 8: e82236. PMID 24349229 DOI: 10.1371/journal.pone.0082236  0.44
2013 Khor GH, Froemming GR, Zain RB, Abraham MT, Omar E, Tan SK, Tan AC, Vincent-Chong VK, Thong KL. DNA methylation profiling revealed promoter hypermethylation-induced silencing of p16, DDAH2 and DUSP1 in primary oral squamous cell carcinoma. International Journal of Medical Sciences. 10: 1727-39. PMID 24155659 DOI: 10.7150/ijms.6884  0.44
2013 Kim J, Yoo M, Kang J, Tan AC. K-Map: connecting kinases with therapeutics for drug repurposing and development. Human Genomics. 7: 20. PMID 24060470 DOI: 10.1186/1479-7364-7-20  0.44
2013 Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. Journal of the National Cancer Institute. 105: 1441-56. PMID 24052618 DOI: 10.1093/jnci/djt209  0.44
2013 Flanigan SA, Pitts TM, Newton TP, Kulikowski GN, Tan AC, McManus MC, Spreafico A, Kachaeva MI, Selby HM, Tentler JJ, Eckhardt SG, Leong S. Overcoming IGF1R/IR resistance through inhibition of MEK signaling in colorectal cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 6219-29. PMID 24045180 DOI: 10.1158/1078-0432.CCR-13-0145  0.44
2013 Anderson RT, Keysar SB, Bowles DW, Glogowska MJ, Astling DP, Morton JJ, Le P, Umpierrez A, Eagles-Soukup J, Gan GN, Vogler BW, Sehrt D, Takimoto SM, Aisner DL, Wilhelm F, ... ... Tan AC, et al. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Molecular Cancer Therapeutics. 12: 1994-2005. PMID 23873848 DOI: 10.1158/1535-7163.MCT-13-0206  0.44
2013 Linger RM, Lee-Sherick AB, DeRyckere D, Cohen RA, Jacobsen KM, McGranahan A, Brandão LN, Winges A, Sawczyn KK, Liang X, Keating AK, Tan AC, Earp HS, Graham DK. Mer receptor tyrosine kinase is a therapeutic target in pre-B-cell acute lymphoblastic leukemia. Blood. 122: 1599-609. PMID 23861246 DOI: 10.1182/blood-2013-01-478156  0.44
2013 Maller O, Hansen KC, Lyons TR, Acerbi I, Weaver VM, Prekeris R, Tan AC, Schedin P. Collagen architecture in pregnancy-induced protection from breast cancer. Journal of Cell Science. 126: 4108-10. PMID 23843613 DOI: 10.1242/jcs.121590  0.44
2013 Spreafico A, Tentler JJ, Pitts TM, Tan AC, Gregory MA, Arcaroli JJ, Klauck PJ, McManus MC, Hansen RJ, Kim J, Micel LN, Selby HM, Newton TP, McPhillips KL, Gustafson DL, et al. Rational combination of a MEK inhibitor, selumetinib, and the Wnt/calcium pathway modulator, cyclosporin A, in preclinical models of colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 4149-62. PMID 23757356 DOI: 10.1158/1078-0432.CCR-12-3140  0.44
2013 Andrysik Z, Kim J, Tan AC, Espinosa JM. A genetic screen identifies TCF3/E2A and TRIAP1 as pathway-specific regulators of the cellular response to p53 activation. Cell Reports. 3: 1346-54. PMID 23684607 DOI: 10.1016/j.celrep.2013.04.014  0.44
2013 Keysar SB, Astling DP, Anderson RT, Vogler BW, Bowles DW, Morton JJ, Paylor JJ, Glogowska MJ, Le PN, Eagles-Soukup JR, Kako SL, Takimoto SM, Sehrt DB, Umpierrez A, Pittman MA, ... ... Tan AC, et al. A patient tumor transplant model of squamous cell cancer identifies PI3K inhibitors as candidate therapeutics in defined molecular bins. Molecular Oncology. 7: 776-90. PMID 23607916 DOI: 10.1016/j.molonc.2013.03.004  0.44
2013 Schlegel J, Sambade MJ, Sather S, Moschos SJ, Tan AC, Winges A, DeRyckere D, Carson CC, Trembath DG, Tentler JJ, Eckhardt SG, Kuan PF, Hamilton RL, Duncan LM, Miller CR, et al. MERTK receptor tyrosine kinase is a therapeutic target in melanoma. The Journal of Clinical Investigation. 123: 2257-67. PMID 23585477 DOI: 10.1172/JCI67816  0.44
2013 Pitts TM, Kulikowski GN, Tan AC, Murray BW, Arcaroli JJ, Tentler JJ, Spreafico A, Selby HM, Kachaeva MI, McPhillips KL, Britt BC, Bradshaw-Pierce EL, Messersmith WA, Varella-Garcia M, Eckhardt SG. Association of the epithelial-to-mesenchymal transition phenotype with responsiveness to the p21-activated kinase inhibitor, PF-3758309, in colon cancer models. Frontiers in Pharmacology. 4: 35. PMID 23543898 DOI: 10.3389/fphar.2013.00035  0.44
2013 Bradshaw-Pierce EL, Pitts TM, Tan AC, McPhillips K, West M, Gustafson DL, Halsey C, Nguyen L, Lee NV, Kan JL, Murray BW, Eckhardt SG. Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal Cancer. Frontiers in Pharmacology. 4: 22. PMID 23524533 DOI: 10.3389/fphar.2013.00022  0.44
2013 Harvell DM, Kim J, O'Brien J, Tan AC, Borges VF, Schedin P, Jacobsen BM, Horwitz KB. Genomic signatures of pregnancy-associated breast cancer epithelia and stroma and their regulation by estrogens and progesterone. Hormones & Cancer. 4: 140-53. PMID 23479404 DOI: 10.1007/s12672-013-0136-z  0.44
2013 Singleton KR, Kim J, Hinz TK, Marek LA, Casás-Selves M, Hatheway C, Tan AC, DeGregori J, Heasley LE. A receptor tyrosine kinase network composed of fibroblast growth factor receptors, epidermal growth factor receptor, v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, and hepatocyte growth factor receptor drives growth and survival of head and neck squamous carcinoma cell lines. Molecular Pharmacology. 83: 882-93. PMID 23371912 DOI: 10.1124/mol.112.084111  0.44
2013 Diamond JR, Eckhardt SG, Tan AC, Newton TP, Selby HM, Brunkow KL, Kachaeva MI, Varella-Garcia M, Pitts TM, Bray MR, Fletcher GC, Tentler JJ. Predictive biomarkers of sensitivity to the aurora and angiogenic kinase inhibitor ENMD-2076 in preclinical breast cancer models. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 19: 291-303. PMID 23136197 DOI: 10.1158/1078-0432.CCR-12-1611  0.44
2012 Giles ED, Wellberg EA, Astling DP, Anderson SM, Thor AD, Jindal S, Tan AC, Schedin PS, Maclean PS. Obesity and overfeeding affecting both tumor and systemic metabolism activates the progesterone receptor to contribute to postmenopausal breast cancer. Cancer Research. 72: 6490-501. PMID 23222299 DOI: 10.1158/0008-5472.CAN-12-1653  0.44
2012 Casás-Selves M, Kim J, Zhang Z, Helfrich BA, Gao D, Porter CC, Scarborough HA, Bunn PA, Chan DC, Tan AC, DeGregori J. Tankyrase and the canonical Wnt pathway protect lung cancer cells from EGFR inhibition. Cancer Research. 72: 4154-64. PMID 22738915 DOI: 10.1158/0008-5472.CAN-11-2848  0.44
2012 Sullivan KD, Padilla-Just N, Henry RE, Porter CC, Kim J, Tentler JJ, Eckhardt SG, Tan AC, DeGregori J, Espinosa JM. ATM and MET kinases are synthetic lethal with nongenotoxic activation of p53. Nature Chemical Biology. 8: 646-54. PMID 22660439 DOI: 10.1038/nchembio.965  0.44
2012 Arcaroli JJ, Quackenbush KS, Powell RW, Pitts TM, Spreafico A, Varella-Garcia M, Bemis L, Tan AC, Reinemann JM, Touban BM, Dasari A, Eckhardt SG, Messersmith WA. Common PIK3CA mutants and a novel 3' UTR mutation are associated with increased sensitivity to saracatinib. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 18: 2704-14. PMID 22553375 DOI: 10.1158/1078-0432.CCR-11-3167  0.44
2012 Arcaroli JJ, Powell RW, Varella-Garcia M, McManus M, Tan AC, Quackenbush KS, Pitts TM, Gao D, Spreafico A, Dasari A, Touban BM, Messersmith WA. ALDH+ tumor-initiating cells exhibiting gain in NOTCH1 gene copy number have enhanced regrowth sensitivity to a γ-secretase inhibitor and irinotecan in colorectal cancer. Molecular Oncology. 6: 370-81. PMID 22521243 DOI: 10.1016/j.molonc.2012.03.004  0.44
2012 Tentler JJ, Tan AC, Weekes CD, Jimeno A, Leong S, Pitts TM, Arcaroli JJ, Messersmith WA, Eckhardt SG. Patient-derived tumour xenografts as models for oncology drug development. Nature Reviews. Clinical Oncology. 9: 338-50. PMID 22508028 DOI: 10.1038/nrclinonc.2012.61  0.32
Show low-probability matches.